Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma;Verträglichkeit und wirksamkeit einer adjuvanten interferon-alfa-2b- behandlung beim aderhautmelanom

Ophthalmologe

Volumn 103, Issue 6, 2006, Pages 506-511

  Richtig, E ^a   Langmann, G ^a   Schlemmer, G ^a   Mullner K ^a   Papaefthymiou, G ^a   Bergthaler, P ^a   Smolle, J ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Adjuvant treatment; Efficacy; Interferon alfa; Safety; Uveal melanoma

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART DISEASE; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FUNCTION; MALE; METASTASIS; OUTCOME ASSESSMENT; SEX DIFFERENCE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT WITHDRAWAL; UVEA MELANOMA; VERTIGO;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MELANOMA; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UVEAL NEOPLASMS;

EID: 33745162968     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-006-1350-7     Document Type: Article

References (30)

1. Aaberg TM Jr (1999) Current clinical management options for uveal melanoma. Ophthalmol Clin North Am 12: 177-182
2. Bechrakis NE, Scheibenbogen C, Schmittel A et al. (2002) Aderhautmelanom. Adjuvante Therapie bei Hochrisikopatienten und neue Therapieansätze im metastasierten Stadium. Ophthalmologe 99: 333-337
3. Bornfeld N (1992) Diagnose und Therapie maligner Melanome der Uvea (Aderhaut und Ziliarkörper). Ophthalmologe 89: W61-78
4. Char DH, Kroll SM, Miller T et al. (1996) Irradiated uveal melanomas: cytopathologic correlation with prognosis. Am J Ophthalmol 122: 509-513
5. Char DH, Kroll S, Phillips TL (1997) Uveal Melanoma. Growth rate and prognosis. Arch Ophthalmol 115: 1014-1018
6. Damato B (1999) The management of uveal melanoma in the next millennium. Ophthalmol Clin North Am 12: 493-506
7. Dithmar S, Rusciano D, Lynn MJ et al. (2000) Neoadjuvant Interferon alfa-2b treatment in a murine model for metastatic ocular melanoma. Arch Ophthalmol 118: 1085-1089
8. Eggermont AM. (2002) European approach to the treatment of malignant melanoma. Curr Opin Oncol 14: 205-211
9. Garbe C, Krasagakis K, Zouboulis CC et al. (1990) Antitumor activities of interferon alpha, beta and gamma and their combinations on human melanoma cells in vitro: Changes in proliferation, melanin synthesis and immunophenotype. J Invest Dermatol 95(Suppl 6): S231-237
10. Gragoudas ES, Egan KM, Seddon JM et al. (1991) Survival of patients with metastases from uveal melanoma. Ophthalmology 98: 383-389
11. Grob JJ, Dreno B, de la Salmoniere P et al. (1998) Randomised trial of interferon alpha-2b as adjuvant therapy in resected primary melanoma thicker than 1,5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351: 1905-1910
12. Günalp I, Batioglu F (1998) Effect of pre-enucleation irridation on the survival of patients with uveal melanoma. Ophthalmologica 212: 231-235
13. Jäckel A, Bock M, Deichmann M et al. (2001) Therapie des metastasierten malignen Uveamelanoms. Hautarzt 52: 98-103
14. Kath R, Hayungs J, Bornfeld N et al. (1993) Prognosis and treatment of disseminated uveal melanoma. Cancer 2: 2219-2223
15. Kirkwood JM, Strawderman MH, Ernstoff MS et al. (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7-17
16. Kirkwood JM, Ibrahim JG, Sondak VK et al. (2000) High- and low-dose Interferon Alfa-2b in high-risk melanoma: First analysis of intergroup Trial E1690/S9111/C9190. J Clin Oncol 18: 2444-2458
17. Langmann G, Pendl G, Müllner K et al. (2000) Gamma Knife radiosurgery for uveal melanomas: an 8 - year experience. J Neurosurg 93 (Suppl 3): S184-188
18. Langmann G, Mosböck G, Stücklschweiger G et al. (2002) Über den Stellenwert der Ruthenium-106-Brachytherapie bei der Therapie von Aderhautmelanomen. Spektrum Augenheilkd 16: 2-5
19. Langmann G, Wackernagel W, Stücklschweiger G (2004) Dosis-Volumen-Histogramm-Regressionsanalysevon Aderhautmelanomen nach einzeitiger Leksell-Gamma-Knife-Radiochirurgie. Ophthalmologe 101: 1111-1120
20. Langmann G, Lechner H, Wenzel E et al. (2005) Transpupillare Thermotherapie (TTT) von Aderhautmelanomen. Langzeitergebnisse einer alleinigen TTT mit einem Adapter für einen konventionellen Infrarotlaser. Ophthalmologe 102: 1162-1167
21. Lommatzsch PK, Alberti W, Lommatzsch R et al. (1994) Radiation effects on the optic nerve observed after brachytherapy of choroidal melanomas with 106Ru/106Rh plaques. Graefes Arch Clin Exp Ophthalmol 232: 482-487
22. McLean IW, Foster WD, Zimmerman L E (1982) Uveal melanoma: location, size, cell type and enucleation as risk factors in metastasis. Hum Pathol 13: 123-132
23. th NCI-EORTC Symp. New Drugs Cancer Ther. Amsterdam, Niederlande, 16.-19. Juni
24. Pehamberger H, Soyer HP, Steiner A et al. (1998) Adjuvant Interferon Alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 16: 1425-1429
25. Russell-Jones R. (2000) Interferon-alpha therapy for Melanoma. Clin Exp Dermatol 25 No 1: 1-6
26. Schuchter LM (2004) Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? J Clin Oncol 22: 7-10
27. Shields CL, Shields JA, Cater J et al. (1998) Transpupillary thermotherapy for choroidal melanoma: Tumor control and visual results in 100 consecutive cases. Ophthalmology 105: 581-590
28. Sieving PA. (2001) Fifteen years of work: the COMS outcomes for medium-sized choroidal melanoma. Arch Ophthalmol 119: 1067-1068
29. Tallberg Th, Uusitalo R, Sarna S et al. (2000) Improvement of the recurrence-free interval using biological adjuvant therapie in uveal melanoma. Anticancer Res 20: 1969-1976
30. Wöll E, Bedikian A, Legha SS (1999) Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 9: 575-581